Every waking minute of Hannah Wilkinson’s day is filled with intense hunger. — -- Every waking minute of Hannah Wilkinson’s day is filled with intense hunger. “Even if she's just eaten, we can … ...
SGLT2 inhibitors significantly improved glycaemic control and reduced the albumin-to-creatinine ratio without affecting body weight in patients with Prader-Willi syndrome and type 2 diabetes (T2D); ...
Prader-Willi syndrome (PWS) is a rare genetic neurodevelopmental disorder caused by an abnormality in the gene expression on chromosome 15. The Prader-Willi Syndrome Association USA estimates that PWS ...
REDWOOD CITY, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Hosted on MSN
Soleno Therapeutics Shares Surge After Competitor’s Prader-Willi Treatment Misses Endpoint
Soleno Therapeutics (NASDAQ:SLNO) saw its stock climb 14% following news that Acadia Pharmaceuticals’ (NASDAQ:ACAD) Phase 3 trial for a Prader-Willi syndrome therapy failed to meet its primary ...
(RTTNews) - Tonix Pharmaceuticals Holding Corp. (TNXP) on Monday said it plans to start a Phase 2 study of TNX-2900 for the treatment of Prader-Willi syndrome, a genetic disorder that affects multiple ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback